Qualy #61 - Rapamycin in cancer treatment

Nov 19, 2019 Episode Page ↗
Overview

This Qualys episode features a discussion with Matt Kaeberlein, Ph.D., exploring rapamycin's complex effects on cancer and aging, highlighting its limited efficacy for diagnosed cancers and dose-dependent, sex-specific outcomes in mouse studies. It also emphasizes immune function as a key driver in age-related cancer prevention.

At a Glance
2 Insights
10m 14s Duration
5 Topics
3 Concepts

Deep Dive Analysis

Rapamycin's Efficacy in Diagnosed Cancers

High-Dose Rapamycin Study in Mice: Sex-Specific Effects

Female Mouse Sensitivity to Rapamycin Dosing

Potential of Rapamycin in Cancer Immune Therapies

Debate: Primary Drivers of Age-Related Cancer Increase

mTOR Inhibition

Turning down the mTOR pathway, often with drugs like rapamycin, is expected to stop cell proliferation. However, cancer cells can evolve to ignore this signal, making mTOR inhibition less effective in advanced cancers.

Immune Surveillance

This is the body's mechanism where the immune system identifies and destroys abnormal cells, including nascent cancer cells, before they can develop into tumors. Its decline with age is considered a significant factor in age-related cancer.

Hematopoietic Cancers

These are cancers that affect the blood, bone marrow, and lymph nodes, such as leukemia and lymphoma. In a high-dose rapamycin mouse study, female mice developed aggressive forms of these cancers.

?
Is rapamycin effective against diagnosed cancers?

For most cancers once diagnosed, rapamycin has been disappointing in its effectiveness, suggesting that tumors may have evolved to ignore mTOR inhibition.

?
How does rapamycin affect the immune system in the context of cancer?

Rapamycin can potentially boost age-related immune function and enhance immune surveillance, which could be anti-cancer. However, very high doses might inhibit immune function, potentially promoting or amplifying cancers.

?
Are there sex-specific differences in response to rapamycin?

Yes, in mice, females appear to be more sensitive to rapamycin, potentially clearing the drug slower or experiencing a greater mTOR inhibitory effect at the same dose, leading to different outcomes at high doses.

?
What are the primary drivers of increased cancer incidence with age?

It's likely a combination of factors, including the reduction in immune surveillance, the length of time to accumulate mutations, and the frequency of mutations. The decline in immune function is considered a very important factor.

1. Seek Professional Medical Advice

Do not use this podcast’s information as a substitute for professional medical advice, diagnoses, or treatment; always seek assistance from your healthcare professionals for any medical conditions you have.

2. Boost Immune Function

Prioritize maintaining a strong immune system, as it is considered a primary anti-cancer mechanism and may be more controllable than other factors like mutation accumulation.

for most cancers once it's reached the point of diagnosis that rapamycin is disappointing in its effectiveness it's not particularly effective

Matt Kaeberlein, Ph.D.

my guess is that because we pushed the dose so high we might have actually taken it too far in the female

Matt Kaeberlein, Ph.D.

immune surveillance is probably the most important anti-cancer mechanism or certainly one of the most important anti-cancer mechanisms

Matt Kaeberlein, Ph.D.

i secretly want that to be the biggest driver because i think we have a better chance to control that

Peter Attia, MD
8 milligrams per kilogram (mg/kg)
Rapamycin dose (high) Daily injection given to mice for three months (from 20 to 23 months of age) in a specific aging study.
60 percent
Lifespan increase (male mice) Observed in male mice after a three-month high-dose rapamycin treatment (8 mg/kg daily injection) ended.
60 percent
Non-hematopoietic cancers (vehicle-treated mice) Percentage of control mice (not given rapamycin) that developed non-hematopoietic cancers in the high-dose study.
0 percent
Non-hematopoietic cancers (rapamycin-treated female mice) None of the female mice treated with high-dose rapamycin developed non-hematopoietic cancers in the study, though they all developed aggressive hematopoietic cancers.
9 times higher than ITP tested dose
Rapamycin dose (lower) A lower dose tested in another study that showed increases in lifespan in both male and female mice of roughly the same magnitude.